# JUL 1 3 2010

# Zeus Scientific Inc. 510K Summary:

# AtheNA Multi-Lyte $\textcircled{8}$ ToRCH IgG Plus Test System

# Administrative Information

1. 510(k): number: k093784

Submission Purpose: Intent to market referenced device for the simultaneous qualitative detection and differentiation of specific human IgG class antibodies to Toxoplasma gondii (Toxo), Rubella, Cytomegalovirus (CMV) and Herpes Simplex 1 (HSV-1) and Herpes Simplex 2 (HSV-2).

3.Measurand: Toxoplasma, Rubella, CMV, HSV 1 and HSV 2 IgG antibodies.

Type of Test: Multiplex microparticle immunoassay.

5. Applicant: Zeus Scientific, Inc. (Zeus), PO Box 38, Raritan, NJ 08869 (908)526-3744

Proprietary Name: AtheNA Multi-Lyte® ToRCH IgG Plus Test System.

Established name: Toxoplasma, Rubella, Cytomegalovirus, Herpes Simplex 1 and Herpes Simplex 2 serological reagents

# Regulatory Information

Toxo   
Device Classification: Enzyme Linked Immunoabsorbent Assay   
Regulation Description: Toxoplasma gondii serological reagents   
Class: Class 2   
Product Code: LGD   
Panel: Microbiology   
Regulation Number: 866.3780   
Rubella   
Device Classification: Enzyme Linked Immunoabsorbent Assay   
Regulation Description: Rubella virus serological reagents   
Class: Class 2   
Product Code: LFX   
Panel: Microbiology   
Regulation Number: 866.3510   
CMV   
Device Classification: Enzyme Linked Immunoabsorbent Assay   
Regulation Description: Cytomegalovirus serological reagents   
Class: Class 2   
Product Code: LFZ   
Panel: Microbiology   
Regulation Number: 866.3175   
Device Classification: Enzyme Linked Immunoabsorbent Assay   
Regulation Description: Herpes Simplex virus serological reagents   
Class: Class 2   
Product Code: MXJ   
Panel: Microbiology   
Regulation Number: 866.3305   
HSV-2   
Device Classification: Enzyme Linked Immunoabsorbent Assay   
Regulation Description: Herpes Simplex 2 serological reagents   
Class: Class 2   
Product Code: MYF   
Panel: Microbiology   
Regulation Number: 866.3305

# Intended Use

The Zeus Scientific, Inc. AtheNA Multi-Lyte® ToRCH IgG Plus Test System is intended for the qualitative detection of specific human IgG class antibodies to Toxoplasma gondii (T.gondi), Rubella, Cytomegalovirus (CMV) and HSV 1 & 2 in human serum. The results of this assay are intended to be used as an aid in the assessment of serological status to Toxoplasma gondii Rubella and CMV. For HSV 1 and HSV 2, the test is indicated or sexually active adults and expectant mothers, as an aid or premptively diagnosing Herpes Simplex 1 and Herpes Simplex 2.

The test is not intended for use in screening blood or plasma donors.

The performance of this assay has not been established for use in a pediatric population, neonatal screening, immunocompromised or immunosuppressed patients or for use at point of care facilities.

# Device Description

The Zeus Scientific, Inc. AtheNA Multi-Lyte® ToRCH IgG Plus Test System is a multiplex immunoassay intended for the simultaneous qualitative detection and differentiation of specific human IgG class antibodies to Toxoplasma gondi, Rubella, Cytomegalovirus (CMV), Herpes Simplex 1 (HSV-1) and Herpes Simplex 2 (HSV-2) in human serum. The results of this assay are intended to be used as an aid in the assessment of a patient's serological status to infection with Toxoplasma gondii, Rubella, CMV, HSV 1 and HSV 2 and in the determination of immune status of individuals including pregnant women. The test system is comprised of the AtheNA Multi-Lyte test kit, software and the Luminex Corp instrument.

The AtheNA Multi-Lyte ToRCH IgG Plus Test System provides the following components:

# Reactive Reagents:

All reactive reagents contain sodium azide as a preservative at a concentration of $0 . 1 \% ( w / v )$ . 1Multiplexed bead suspension 1. Ready to use, $5 . 5 m L$ bottle. The suspension contains separate distinguishable 5.6 micron polystyrene beads that are conjugated with:

Toxo grade 2 antigen

• Rubella K2S grade antigen CMV grade 2   
• HSV-1 type-specific recombinant gG-1 protein antigen   
• HSV-2 gG-2 type-specific recombinant gG-2 protein antigen

The bead mix also contains one bead set designed to detect non-specific antibodies in the patient sample (if present) and four separate bead sets used for assay calibration.

Conjugate: Phycoerythrin conjugated goat anti-human IgG (y chain specific).Ready to use, 15 mL amber bottle.   
3.Human positive serum control 1. One, $0 . 2 ~ \mathsf { m L }$ vial.   
4. Human positive serum control 2. One, $0 . 2 ~ \mathsf { m L }$ vial.   
5.Human negative serum control. One, $0 . 2 ~ \mathsf { m L }$ vial.   
6. SAVe Diluent®. One $5 0 m l$ bottle containing phosphate-buffered-saline. Ready to use. NOTE, the sample diluent will change color in the presence of serum.   
7. Wash Buffer Concentrate: dilute 1 part concentrate $+ 9$ parts deionized or distilled water. One bottle containing ${ \mathfrak { 1 0 } } \times$ concentrate of phosphate buffered saline.

# Non-Reactive Reagents

One, 96-well filtration plate for rinsing the microspheres   
Data Labels:One label is adhered to the inside lid of the kit box and a econd label is inside the ki box.   
Package Insert providing instructions for use   
Calibration CD: a compact disc that includes all lot-specific kit calibration values required for specimen analysis and assay quality control

# Substantial Equivalence

Examination of enclosed data indicates that the Zeus Scientific, Inc AtheNA Multi-Lyte ToRCH IgG Plus Test System forhe simultaneous detection and differentiation of IgG class antibodies to Toxo, Rubella, CMV, HSV-1 and HSV-2 is substantially equivalent to commercially marketed test systems which have been previously cleared by the FDA for in vitro diagnostic use.

The comparator information for both cleared and investigational analytes are listed:

# Toxoplasma

Name of Predicate Device: Toxo IgG ELISA Test System Manufacturer of Predicate Device: Zeus Scientific, Inc. 3. 510(k)891781

# Rubella

Name of Predicate Device: Rubella IgG ELISA Test System Manufacturer of Predicate Device: Zeus Scientific, Inc. 3. 510(k)891783

# CMV

Name of Predicate Device: CMV IgG ELISA Test System Manufacturer of Predicate Device: Zeus Scientific, Inc.

3. 510(k)924096

# HSV-1

Name of Predicate Device: HerpeSelect 1 and 2 Immunoblot IgG Manufacturer of Predicate Device: Focus Diagnostics 3. 510(k)000238

# HSV-2

Name of Predicate Device: HerpeSelect 1 and 2 Immunoblot IgG 2Manufacturer of Predicate Device: Focus Diagnostics 3. 510(k)000238

# Test Principle

The Zeus Scientific, Inc. AtheNA Multi-Lyte ToRCH IgG Plus Test System is designed to detect IgG class antibodies in human sera to Toxo, Rubella, CMV, HSV-1 and HSV-2. The test procedure involves four incubation steps:

Patient sera are diluted and the diluted test sera are incubated in a vessel containing a multplexed mixture of the bead suspension. The multiplexed bead suspension contains a mixture of distinguishable sets of polystyrene microspheres; each set conjugated with Toxoplasma, Rubella, CMV, HSV-1 and HSV-2 antigens. The bead mix also contains one bead set designed to detect nonspeiic antibodies in the patient sample if present) and four separate bead sets used for assay calibration. If present in patient sera, the individual antibodies will bind to the corresponding immobilized antigen bead set. The microspheres are rinsed to remove non-reactive serum proteins. Phycoerythrin-conjugated goat anti-human IgG is added to the vessel and the plate is incubated.The conjugate will react with IgG antibody immobilized on the beads in step 1. The bead suspension is then analyzed by the AtheNA Multi-Lyte $\otimes$ instrument. The bead set(s) are sorted (identified) and the amount of reporter molecule (PE conjugate) is determined for each bead set. Using the IntraWell Calibration Technology®, internal calibration bead sets are used to to convert raw fluorescence into outcome (units).

# Analytical Specificity Interfering Substances

The efect o potential interfering substances on sample results enerated using theAtheNA Multi-Lyte te sstm was valuatd with e ollowg possilnt bstancs basn the uilis .

Te quantyanaly n  inter ustanc  as follws n s ba n CL E7-A:

Bilirubin: 1mg/dL (low), 15 mg/dL (high)

Albumin: 3.5 g/dL (low), 5 g/dL (high) Cholesterol: 150 mg/dL (low), 250 mg/dL (high) Triglycerides: 150 mg/dL (low), 500 mg/dL (high) Hemoglobin: 20 g/dL (low), 20 g/dL (high) Intralipid: 300 mg/dL (low), 750 mg/dL (high)

Three samples each for Toxo, Rubella, CMV, HSV 1 and 2 IgG were chosen based on their performance on the AtheNA Multi-Lyte test system: positive, borderline and negative. The samples were exposed to the possible interfering substance and tested. All samples showed less than a $20 \%$ change in signal with the following exceptions:

<table><tr><td rowspan="2"></td><td colspan="11">  S   hanS a %</td></tr><tr><td colspan="2">Bilirubin</td><td colspan="2">Albumin</td><td colspan="2">Cholesterol</td><td colspan="2">Triglycerides</td><td colspan="2">Hemoglobin</td><td colspan="2">Intralipid</td></tr><tr><td>Analyte/Level of Sample</td><td>High</td><td>low</td><td>High</td><td>Low</td><td>High</td><td>Low</td><td>High</td><td>Low</td><td>High</td><td>Low</td><td>High</td><td>Low</td></tr><tr><td>Toxoplasma Positive</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>22%</td><td>&lt;20%</td><td>&lt;20%</td></tr><tr><td>Toxoplasma Borderline</td><td>&lt;20%</td><td>&lt;20%</td><td>-33%</td><td>-30%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td></tr><tr><td>Toxoplasma Negative</td><td>&lt;20%</td><td>&lt;20%</td><td>78%</td><td>89%</td><td>31%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>22%</td><td>78%</td><td>&lt;20%</td></tr><tr><td>Rubellia Positive</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>24%</td><td>&lt;20%</td><td>&lt;20%</td></tr><tr><td>Rubella Borderine</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>-27%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>-31%</td><td>&lt;20%</td><td>&lt;20%</td></tr><tr><td>Rubella Negative</td><td>50%</td><td>50%</td><td>&lt;20%</td><td>-33%</td><td>&lt;20%</td><td>-33%</td><td>-33%</td><td>-33%</td><td>&lt;20%</td><td>-33%</td><td>&lt;20%</td><td>&lt;20%</td></tr><tr><td>CMV Positive</td><td>&lt;20%</td><td>&lt;20%</td><td>·27%</td><td>-25%</td><td>-32%</td><td>-31%</td><td>&lt;20%</td><td>&lt;20%</td><td>-33%</td><td>-35%</td><td>&lt;20%</td><td>&lt;20%</td></tr><tr><td>CMV Borderline</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>31%</td><td>24%</td><td>&lt;20%</td></tr><tr><td>CMV Negative</td><td>&lt;20%</td><td>25%</td><td>&lt;20%</td><td>32%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>25%</td><td>&lt;20%</td><td>25%</td></tr><tr><td>HSV 1 Postive</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>27%</td><td>22%</td><td>&lt;20%</td><td>&lt;20%</td></tr><tr><td>HSV 1 Borderline</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td></tr><tr><td>HSV 1 Negative</td><td>&lt;20%</td><td>&lt;20%</td><td>41%</td><td>36%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>20%</td><td>56%</td><td>26%</td><td>&lt;20%</td><td>&lt;20%</td></tr><tr><td>HSV 2 Positive</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>27%</td><td>&lt;20%</td><td>24%</td><td>21%</td><td>&lt;20%</td><td>23%</td><td>&lt;20%</td><td>&lt;20%</td></tr><tr><td>HSV 2 Borderline</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td></tr><tr><td>HSV 2 Negative</td><td>50%</td><td>41%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>&lt;20%</td><td>32%</td><td>35%</td><td>&lt;20%</td><td>&lt;20%</td></tr></table>

# Cross Reactivity

Studies were performed at the manufacturing facility to assess cross reactivity with the Athena MultiLyte ToRCH IgG Plus test system using samples that were sero-positive to Measles, Mumps, Rubella, VZV, EBV VCA IgG, EBNA-1, HSV-1, HSV-2, CMV, Syphilis, Toxoplasma and ANA and Rf IgM. Micro-particle and ELISA immunoassay test systems manufactured for commercial distribution were used to determine the sero-positivity of the samples. Ten samples minimally for each possible cross-reactant were tested. The results presented were obtained by testing the analytes against high concentrations of possible cross reactants.

<table><tr><td></td><td colspan="5">AtheNA Multi-Lyte ToRCH IgG Plus Cross Reactivity Summary</td></tr><tr><td>Analyte</td><td>Toxoplasma</td><td>Rubella</td><td>CMV</td><td>HSV 1</td><td>HSV 2</td></tr><tr><td>Measles</td><td>0/10</td><td>0/20</td><td>0/10</td><td>0/10</td><td>0/10</td></tr><tr><td>Mumps</td><td>0/10</td><td>0/20</td><td>0/10</td><td>0/10</td><td>0/10</td></tr><tr><td>Rubella</td><td>0/10</td><td>N/A</td><td>0/10</td><td>0/10</td><td>0/10</td></tr><tr><td>VZV</td><td>0/10</td><td>0/20</td><td>0/10</td><td>0/10</td><td>0/10</td></tr><tr><td>VCA IgG</td><td>0/10</td><td>0/20</td><td>0/10</td><td>0/10</td><td>0/10</td></tr><tr><td>EBNA IgG</td><td>0/10</td><td>0/20</td><td>0/10</td><td>0/10</td><td>0/10</td></tr><tr><td>HSV 1</td><td>0/10</td><td>0/20</td><td>0/10</td><td>N/A</td><td>0/10</td></tr><tr><td>HSV 2</td><td>0/10</td><td>0/20</td><td>0/10</td><td>0/10</td><td>N/A</td></tr><tr><td>ANA</td><td>0/10</td><td>0/4</td><td>0/10</td><td>0/10</td><td>0/10</td></tr><tr><td>RF</td><td>0/10</td><td>0/10</td><td>0/10</td><td>0/10</td><td>0/10</td></tr><tr><td>CMV</td><td>0/10</td><td>0/20</td><td>N/A</td><td>0/10</td><td>0/10</td></tr><tr><td>Syphilis</td><td>0/10</td><td>0/10</td><td>0/10</td><td>0/10</td><td>0/10</td></tr><tr><td>Toxoplasma</td><td>NA</td><td>0/20</td><td>0/10</td><td>0/10</td><td>0/10</td></tr></table>

# Clinical Performance

# Clinical Data Generated for Submission

1. Comparative testing of the Intended Use Populations: AtheNA Multi-Lyte ToRCH IgG Plus versus predicate assays. 851 unselected samples submitted for ToRCH testing were obtained from various serum vendors. The samples were submitted for ToRCH antibody testing, sequentially numbered, de-identified and archived and made available for purchase. After procurement, 300 samples were tested at a hospital laboratory located in the Mid-Atlantic region; 351 samples were tested at a hospital laboratory located in the Northeast. 200 samples were from Expectant Mothers and were tested at the manufacturing site's laboratory. All results are from data generated concurrently using the AtheNA Multi-Lyte ToRCH IgG Plus test system.   
2. Comparative testing in Populations other than those for Intended Use: Additional clinical performance was assessed in special populations other than the intended use populations. Performance data was gathered on HSV-1 and HSV-2 low prevalence populations and the relative specificity of Rubella was assessed internally at Zeus using pre-selected banked samples of sera which previously tested negative for Rubella antibody by the predicate device   
3. Clinical performance with International Standards and CDC Reference Panels: Performance of the AtheNA Multi-Lyte ToRCH IgG Plus was assessed using the CDC Reference Panels. Traceability and linearity was demonstrated for Rubella using the WHO standard. The performance of Rubella IgG was demonstrated using the CDC low titer standard.   
4. Precision and Reproducibility: Precision of the device was assessed using nine samples. These repeatability sudies were performe internally at the manufacturing site's lboratory. Reproducibility was assessed using six samples tested at three sites, two external and one internal.

# Expected Results

Observed prevalence was evaluated at three sites in a prospective study including individuals and pregnant women undergoing ToRCH testing.

651 masked samples prospectively collected from individuals between the ages of ${ < } 1$ and 89 were tested at two external sites. 300 samples were submitted for ToRCH antibody assessment. 351 samples were submitted for testing of one or more of the anlytes in the ToRCH panel. Testng was performed on all five markers on all samples. Results from a subset of 596/651 individuals between the ages of 17 and 69 were used to calculate HSV 1 and HSV 2 prevalence. Site 1, a hospital laboratory located in the Mid-Atlantic region tested 300 samples. Site 2, a hospital laboratory in the Northeast tested 351 samples.

200 masked samples prospectively coilected from pregnant women for ToRCH antibody assessment were obtained from two serum vendors. The women ranged in age from 15 to 46.The samples were tested internally at the manufacturer site for all five analytes.

# AtheNA Multi-Lyte ToRCH IgG Plus Observed Prevalence in Intended Use Populations

Observed Prevalence in Individuals Undergoing ToRCH Antibody Assessment   

<table><tr><td colspan="8">Prevalence of Analytes in Prospective Samples</td></tr><tr><td></td><td></td><td colspan="2">Toxoplasma</td><td colspan="2">Rubella</td><td colspan="2">CMV</td></tr><tr><td>Age</td><td>Gender</td><td>Pos/Total</td><td>% Prevalence</td><td>Pos/Total</td><td>% Prevalence</td><td>Pos/Total</td><td>% Prevalence</td></tr><tr><td>0.9</td><td>Male</td><td>0/2</td><td>0.0%</td><td>1/2</td><td>50.0%</td><td>1/2</td><td>50.0%</td></tr><tr><td></td><td>Female</td><td>1/2</td><td>50.0%</td><td>1/2</td><td>50.0%</td><td>1/2</td><td>50.0%</td></tr><tr><td>10-19</td><td>Male</td><td>1/3</td><td>33.3%</td><td>3/3</td><td>100.0%</td><td>2/3</td><td>66.7%</td></tr><tr><td></td><td>Female</td><td>5/55</td><td>9.1%</td><td>50/55</td><td>90.9%</td><td>38/55</td><td>69.1%</td></tr><tr><td>20-29</td><td>Male</td><td>2/24</td><td>8.3%</td><td>23/24</td><td>95.8%</td><td>9/24</td><td>37.5%</td></tr><tr><td>30-39</td><td>Female</td><td>58/257</td><td>22.6%</td><td>232/257</td><td>90.3%</td><td>184/257</td><td>71.6%</td></tr><tr><td></td><td>Male</td><td>3/16</td><td>18.8%</td><td>12/16</td><td>75.0%</td><td>8/16</td><td>50.0%</td></tr><tr><td>40-49</td><td>Female</td><td>57/189</td><td>30.2%</td><td>170/189</td><td>89.9%</td><td>145/189</td><td>76.7%</td></tr><tr><td></td><td>Male</td><td>6/11</td><td>54.5%</td><td>11/11</td><td>100.0%</td><td>8/11</td><td>72.7%</td></tr><tr><td>50-59</td><td>Female</td><td>14/44</td><td>31.8%</td><td>39/44</td><td>88.6%</td><td>30/44</td><td>68.2%</td></tr><tr><td></td><td>Male</td><td>1/10</td><td>10.0%</td><td>9/10</td><td>90.0%</td><td>5/10</td><td>50.0%</td></tr><tr><td>60-69</td><td>Female</td><td>3/11</td><td>27.3%</td><td>10/11</td><td>90.9%</td><td>10/11</td><td>90.9%</td></tr><tr><td></td><td>Male</td><td>3/6</td><td>50.0%</td><td>6/6</td><td>100.0%</td><td>4/6</td><td>66.7%</td></tr><tr><td>70+</td><td>Female</td><td>3/4</td><td>75.0%</td><td>4/4</td><td>100.0%</td><td>3/4</td><td>75.0%</td></tr><tr><td></td><td>Male Female</td><td>0/0 1/1</td><td>0.0% 100.0%</td><td>0/0</td><td>0.0% 100.0%</td><td>0/0</td><td>0.0% 100.0%</td></tr><tr><td>Unkown</td><td>Male</td><td></td><td></td><td>1/1</td><td></td><td>1/1</td><td></td></tr><tr><td>Age</td><td>Female</td><td>0/0 2/13</td><td>0.0% 15.4%</td><td>0/0 9/13</td><td>0.0% 69.2%</td><td>0/0 10/13</td><td>0.0% 76.9%</td></tr></table>

44

<table><tr><td rowspan=1 colspan=1>UnknownGender/Age</td><td rowspan=1 colspan=1>0/3</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>1/3</td><td rowspan=1 colspan=1>33.3%</td><td rowspan=1 colspan=1>3/3</td><td rowspan=1 colspan=1>100.0%</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>160/651</td><td rowspan=1 colspan=1>24.6%</td><td rowspan=1 colspan=1>582/651</td><td rowspan=1 colspan=1>89.4%</td><td rowspan=1 colspan=1>459</td><td rowspan=1 colspan=1>71.0%</td></tr></table>

Observed Prevalence in Pregnant Women   

<table><tr><td colspan="10">Prevalence of Analytes in Pregnant Women</td></tr><tr><td></td><td colspan="2">Toxoplasma</td><td colspan="2">Rubella</td><td colspan="2">CMV</td><td colspan="2">HSV1</td><td colspan="2">HSV 2</td></tr><tr><td>Age</td><td>Pos/Total</td><td>% Prevalence</td><td>Pos/Total :</td><td>% Prevalence</td><td>Pos/Total</td><td>% Prevalence</td><td>Pos/Total</td><td>% Prevalence</td><td>Pos/Totai</td><td>% Prevalence</td></tr><tr><td>16- 19 20- 29</td><td>2/23 12/131</td><td>9.2% 27.0%</td><td>23/23 35/39</td><td>100.0% 89.7%</td><td>16/23 104/131</td><td>69.6% 79.4%</td><td>15/23 92/124</td><td>65.2% 74.2%</td><td>3/23 51/124</td><td>13.0% 41.1%</td></tr><tr><td rowspan="3">30- 39 40- 49</td><td>10/37</td><td>55.6%</td><td>127/129</td><td>28.4%</td><td>26/37</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>70.3%</td><td>30/36</td><td>83.3%</td><td>14/36</td><td>38.9%</td></tr><tr><td>5/9</td><td>8.3%</td><td>9/9</td><td>100.0%</td><td>5/9</td><td>55.6%</td><td>8/9</td><td>88.9%</td><td>7/9</td><td>77.8%</td></tr><tr><td>Total</td><td>29//200</td><td>14.50%</td><td>194/200</td><td>97.90%</td><td>151/200</td><td>75.50%</td><td>160/200</td><td>80.00%</td><td>75/200</td><td>37.50%</td></tr></table>

Observed Prevalence in Sexually Active Adults   

<table><tr><td rowspan=1 colspan=2></td><td rowspan=1 colspan=2>HSV 1</td><td rowspan=1 colspan=2>HSV 2</td></tr><tr><td rowspan=1 colspan=1>Age</td><td rowspan=1 colspan=1>Gender</td><td rowspan=1 colspan=1>Pos/Total</td><td rowspan=1 colspan=1>%Prevalence</td><td rowspan=1 colspan=1>Pos/Total</td><td rowspan=1 colspan=1>%Prevalence</td></tr><tr><td rowspan=1 colspan=1>17-19</td><td rowspan=1 colspan=1>MaleFemale</td><td rowspan=1 colspan=1>.0/027/38</td><td rowspan=1 colspan=1>0.0%71.1%</td><td rowspan=1 colspan=1>0/06/38</td><td rowspan=1 colspan=1>0.0%15.8%</td></tr><tr><td rowspan=1 colspan=1>20-29</td><td rowspan=1 colspan=1>MaleFemale</td><td rowspan=1 colspan=1>6/23180/246</td><td rowspan=1 colspan=1>26.1%73.2%</td><td rowspan=1 colspan=1>1/2357/245</td><td rowspan=1 colspan=1>4.3%23.3%</td></tr><tr><td rowspan=1 colspan=1>30-39</td><td rowspan=1 colspan=1>MaleFemale</td><td rowspan=1 colspan=1>10/16165/187</td><td rowspan=1 colspan=1>62.5%88.2%</td><td rowspan=1 colspan=1>3/1552/187</td><td rowspan=1 colspan=1>20.0%27.8%</td></tr><tr><td rowspan=1 colspan=1>40·49</td><td rowspan=1 colspan=1>MaleFemale</td><td rowspan=1 colspan=1>10/1131/44</td><td rowspan=1 colspan=1>90.9%70.5%</td><td rowspan=1 colspan=1>3/1116/44</td><td rowspan=1 colspan=1>27.3%36.4%</td></tr><tr><td rowspan=1 colspan=1>50-59</td><td rowspan=1 colspan=1>MaleFemale</td><td rowspan=1 colspan=1>5/108/11</td><td rowspan=1 colspan=1>50.0%72.7%</td><td rowspan=1 colspan=1>5/106/11</td><td rowspan=1 colspan=1>50.0%54.5%</td></tr><tr><td rowspan=1 colspan=1>60-69</td><td rowspan=1 colspan=1>MaleFemale</td><td rowspan=1 colspan=1>4/6414</td><td rowspan=1 colspan=1>66.7%100.0%</td><td rowspan=1 colspan=1>2/62/4</td><td rowspan=1 colspan=1>33.3%50.0%</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>450/596</td><td rowspan=1 colspan=1>75.5%</td><td rowspan=1 colspan=1>153/594</td><td rowspan=1 colspan=1>25.8%</td></tr></table>

HSV Hypothetical Predictive Values by Prevalence   

<table><tr><td colspan="2">Sexually Active Adults</td></tr><tr><td>HSV-1</td><td>HSV-2</td></tr></table>

<table><tr><td colspan="2">Expectant Mothers</td></tr><tr><td>• HSV-1</td><td>HSV-2</td></tr><tr><td></td><td></td></tr></table>

45

<table><tr><td>Prevalence</td><td>PPV</td><td>NPV</td><td>PPV .</td><td>NPV</td><td></td><td>PPV</td><td>NPV</td><td>PPV</td><td>NPV</td></tr><tr><td>50.0%</td><td>94.8%</td><td>98.5%</td><td>93.7%</td><td>96.8%</td><td></td><td>87.0%</td><td>99.2%</td><td>92.9%</td><td>97.0%</td></tr><tr><td>40.0%</td><td>92.4%</td><td>99.0%</td><td>90.9%</td><td>97.8%</td><td></td><td>81.7%</td><td>99.5%</td><td>89.7%</td><td>98.0%</td></tr><tr><td>30.0%</td><td>88.7%</td><td>99.4%</td><td>86.5%</td><td>98.6%</td><td></td><td>74.2%</td><td>99.6%</td><td>84.9%</td><td>98.7%</td></tr><tr><td>25.0%</td><td>85.9%</td><td>99.5%</td><td>83.2%</td><td>98.9%</td><td></td><td>69.1%</td><td>99.7%</td><td>81.4%</td><td>99.0%</td></tr><tr><td>20.0%</td><td>82.0%</td><td>99.6%</td><td>78.8%</td><td>99.2%</td><td></td><td>62.6%</td><td>99.8%</td><td>76.6%</td><td>99.2%</td></tr><tr><td>15.0%</td><td>76.3%</td><td>99.7%</td><td>72.5%</td><td>99.4%</td><td></td><td>54.2%</td><td>99.9%</td><td>69.8%</td><td>99.5%</td></tr><tr><td>10.0%</td><td>67.0%</td><td>99.8%</td><td>62.4%</td><td>99.6%</td><td></td><td>42.7%</td><td>99.9%</td><td>59.3%</td><td>99.7%</td></tr><tr><td>5.0%</td><td>49.0%</td><td>99.9%</td><td>44.0%</td><td>99.8%</td><td></td><td>26.1%</td><td>100.0%</td><td>40.8%</td><td>99.8%</td></tr></table>

# Performance in Prospectively Collected Intended Use Populations

The performance of the ToRCH panel was evaluated using prospectively collected frozen remnant serum samples from a total of 651 individuals for which ToRCH IgG panel or testing for each of the individual analytes was ordered. Outside investigators tested 300 and 351 samples respectively.

Summary of Performance Characteristics In Individuals Undergoing ToRCH Antibody Assessment   

<table><tr><td colspan="2" rowspan="2"></td><td colspan="6">Predicate</td></tr><tr><td>Positive</td><td>Equivocal</td><td>Negative</td><td>Site Total</td><td>PPA NPA</td><td>95% C</td></tr><tr><td rowspan="9">A M  ay</td><td>Toxoplasma Positive</td><td>136</td><td>3</td><td>16</td><td>155</td><td>99.3% (136/137)</td><td>96.0% - 100%</td></tr><tr><td>Equivocal Negative</td><td>0 0</td><td>0 1</td><td>3 490</td><td>3 491</td><td>95.7% (450/514)</td><td>98.0% ± 99.9%</td></tr><tr><td>Invalid Site Total</td><td>0</td><td>0</td><td>2</td><td>2</td><td></td><td></td></tr><tr><td></td><td>136</td><td>4</td><td>511</td><td>651</td><td></td><td></td></tr><tr><td colspan="7"></td></tr><tr><td>Rubella Positive</td><td>533</td><td>4</td><td>4</td><td>541</td><td>98.5% (533/541)</td><td>97.1% - 99.4%</td></tr><tr><td>Equlvocal Negative Invalid</td><td>3 2 0</td><td>1 3 0</td><td>1 60 0</td><td>5 65 0</td><td>&#x27;87% (60/69)</td><td>76.7% - 93.9%</td></tr><tr><td>Site Total</td><td>538</td><td>3</td><td>65</td><td>611</td><td></td><td></td></tr><tr><td colspan="7"></td></tr><tr><td>CMV</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Positive</td><td>450</td><td>6</td><td>6</td><td>462</td><td>99.6% (450/452)</td><td>98.4% - 100%</td></tr></table>

46

<table><tr><td rowspan=2 colspan=1>b</td><td rowspan=1 colspan=1>EquivocalNegativeInvalid</td><td rowspan=1 colspan=1>110</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>41810</td><td rowspan=1 colspan=1>71820</td><td rowspan=1 colspan=1>91.3% (181/197)</td><td rowspan=1 colspan=1>87.2% - 95.3%</td></tr><tr><td rowspan=1 colspan=1>Site Total</td><td rowspan=1 colspan=1>452</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>191</td><td rowspan=1 colspan=1>651</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr></table>

.

# HSV1 and HSV2 Performance in Sexually Active Adults

The performance of the HSV1 and HSV2 was evaluated in prospectively collected samples using results from 596/651 individuals between the ages of 17 and 69.

Summary of Performance Characteristics in Sexually Active Adults   

<table><tr><td colspan="2" rowspan="2"></td><td colspan="6">Predicate</td></tr><tr><td>Positive</td><td>Equivocal</td><td>Negative</td><td>Site Total</td><td>Sensitivity Specificity</td><td>95% CI</td></tr><tr><td rowspan="9">Ale M y-l VNuu</td><td>HSV 1</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Positive</td><td>418</td><td>0</td><td>8</td><td>426</td><td>98.6% (418/424)</td><td>97.0% - 99.5%</td></tr><tr><td>Equlvocal</td><td>4</td><td>0</td><td>1</td><td>5</td><td></td><td></td></tr><tr><td>Negative</td><td>2</td><td>0</td><td>163</td><td>165</td><td>94.6% (163/172</td><td>90.3% - 97.6%</td></tr><tr><td>Invalid</td><td>0</td><td>0</td><td>0</td><td>0</td><td></td><td></td></tr><tr><td>Site Total</td><td>424</td><td>0</td><td>172</td><td>596</td><td></td><td></td></tr><tr><td>HSV 2 Positive</td><td></td><td>0</td><td></td><td></td><td>96.9% (127/131)</td><td>92.4% - 98.8%</td></tr><tr><td>Equivocal</td><td>127 1</td><td>0</td><td>27 3</td><td>154 4</td><td></td><td></td></tr><tr><td>Negative</td><td>3</td><td>0</td><td>433</td><td>436</td><td>93.5% (433/463)</td><td>90.9% · 95.6%</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Invalid</td><td>0</td><td>0</td><td>0</td><td>0</td><td></td><td></td></tr><tr><td>Site Total</td><td>131</td><td>0</td><td>463</td><td>594*</td><td></td><td></td></tr></table>

# Performance in Pregnant Women Population

Zeus Scientific internally evaluated 200 frozen remnant serum samples collected from pregnant women between the ages of 15 and 46 for which ToRCH antibody testing was requested.

Summary of Performance Characteristics in a Population of Pregnant Women   

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=6>Predicate</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Site Total</td><td rowspan=1 colspan=1>PPANPA</td><td rowspan=1 colspan=1>95% Cl</td></tr><tr><td rowspan=2 colspan=1>Aii NYSd D0 a1Twseoxo:</td><td rowspan=1 colspan=1>Toxoplasma</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>29</td><td rowspan=1 colspan=1>100.0% (22/22)</td><td rowspan=1 colspan=1>87.3% - 100%</td></tr></table>

47

<table><tr><td rowspan="15"></td><td>Equivocal</td><td>0</td><td>0</td><td>1</td><td>1</td><td rowspan="2">95.3% (170/178)</td><td rowspan="2"></td><td rowspan="2">91.3% - 98.0%</td></tr><tr><td>Negetive</td><td>0</td><td>0</td><td>170</td><td>170</td></tr><tr><td>Invalid</td><td>0</td><td>0</td><td>0</td><td>0</td><td></td><td></td></tr><tr><td>Site Total</td><td>22</td><td>1</td><td>177</td><td>200</td><td></td><td></td></tr><tr><td colspan="7"></td></tr><tr><td>Aubella Positive Indeterminate</td><td>194 1</td><td>0</td><td>0</td><td>194</td><td>99.0% (194/196)</td><td>96.4% - 99.9%</td></tr><tr><td>Negative Invalld</td><td>0 0</td><td>0 1 0</td><td>0 4 0</td><td>1 5 0</td><td>100.0% (4/4)</td><td>47.3% ± 100%</td></tr><tr><td>Site Total</td><td>195</td><td>1</td><td>4</td><td>200</td><td></td><td></td></tr><tr><td colspan="7">CMV</td></tr><tr><td>Positive</td><td>151</td><td>0</td><td>0</td><td>151</td><td>98.1% (151/154)</td><td>94.4% -99.6%</td></tr><tr><td>Equivocat Negatlve</td><td>0 0</td><td>0 3</td><td>0 46</td><td>0 49</td><td>100.0% (46/46)</td><td>93.7% - 100%</td></tr><tr><td>Invalid Site Total</td><td>0 151</td><td>0 3</td><td>0 46</td><td>0 200</td><td></td><td></td></tr><tr><td colspan="7"></td></tr><tr><td>HSV1</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Positive Equivocal</td><td>137 0</td><td>0 0</td><td>8 0</td><td>145 0</td><td>99.3% (137/138)</td><td>96.1% - 100%</td></tr><tr><td>Negative Invalld</td><td>1 0</td><td>0</td><td>46</td><td>47 0</td><td>85.2% (46/54)</td><td>72.3% - 93.4%</td></tr><tr><td>Site Total</td><td>138</td><td>0 0</td><td>0 54</td><td>192</td><td></td><td></td></tr><tr><td>HSV2 Positive</td><td>68</td><td></td><td></td><td></td><td>97.1% (68/70)</td><td>90.1% - 99.7%</td></tr><tr><td>Equivocal Negative</td><td>0 2</td><td>0 0 0</td><td>7 2 113</td><td>75 2 115</td><td>92.6% (113/122</td><td>86.5% - 96.6%</td></tr><tr><td>Invalid Site Total</td><td>0 70</td><td>0 0</td><td>0 122</td><td>0 192</td><td></td><td></td></tr></table>

# Agreement with CDC Panel

The performance of the AtheNA Multi-Lyte ToRCH IgG Plus test system was assessed using masked, well characterized serum panel from the CDC. The panels consist of:

1. $70 \%$ Toxo positive and $30 \%$ Toxo negative samples.

2. EY $80 \%$ Rubella positive and $20 \%$ Rubella negative samples.   
3. $54 \%$ CMV positive and $45 \%$ CMV negative samples.   
4. EPY $2 4 \%$ HSV1 and HSV2 dual-positive samples, $50 \%$ HSV1 positive and $50 \%$ HSV1 negative samples and $4 8 \%$ HSV2 positive and $5 2 \%$ HSV2 negative samples.

The results are presented to convey further information on the performance of the test kit and do not imply endorsement of the assay by the CDC.

#

<table><tr><td colspan="2" rowspan="2">greement with CDC Characterized Serurn Panels</td><td colspan="5">CDC Result</td></tr><tr><td></td><td></td><td></td><td>PPA</td><td></td></tr><tr><td></td><td>Toxoplasma</td><td>Positive</td><td>Negative</td><td>Site Total</td><td>NPA</td><td>95% CI</td></tr><tr><td rowspan="13">AH T H - VN</td><td>Positive</td><td>70</td><td>0</td><td>70</td><td>100.0% (70/70)</td><td>95.8% - 100.0%</td></tr><tr><td>Equivocal</td><td>0</td><td>0</td><td>0</td><td></td><td></td></tr><tr><td>Negative</td><td>0</td><td>30</td><td>30</td><td>100.0% (30/30)</td><td>90.5% - 100.0%</td></tr><tr><td>Invalid</td><td>0</td><td>0</td><td>0</td><td></td><td></td></tr><tr><td>Site Total</td><td>70</td><td>30</td><td>100</td><td></td><td></td></tr><tr><td></td><td colspan="4"></td><td></td></tr><tr><td colspan="5">Rubella</td><td></td></tr><tr><td>Positive</td><td>80</td><td>0</td><td>80</td><td>100.0% (80/80)</td><td>96.3% - 100.0%</td></tr><tr><td>Equlvocal</td><td>0</td><td>0</td><td>0</td><td></td><td></td></tr><tr><td>Negative</td><td>0</td><td>20</td><td>20</td><td>100.0% (20/20)</td><td>86.1% - 100.0%</td></tr><tr><td>Invalid</td><td>0</td><td>0</td><td>0</td><td></td><td></td></tr><tr><td>Site Total</td><td>80</td><td>20</td><td>100</td><td></td><td></td></tr><tr><td colspan="6"></td></tr><tr><td>CMV</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Positive</td><td>52</td><td>2</td><td>54</td><td>100.0% (52/52)</td><td>94.4% - 100.0%</td></tr><tr><td>Equivocal</td><td>0</td><td>0</td><td>0</td><td>95.8% (46/48)</td><td></td></tr><tr><td>Negative Invalid</td><td>0 0</td><td>46</td><td>46 0</td><td></td><td>90.2% · 100.0%</td></tr><tr><td>Site Total</td><td>52</td><td>0 48</td><td>100</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="6"></td></tr><tr><td>HSV1</td><td></td><td></td><td>50</td><td>100.0% (50/50)</td><td>94.2% · 100.0%</td></tr><tr><td>Positive</td><td>50</td><td>0</td><td></td><td></td><td></td></tr><tr><td>Equivocal</td><td>0</td><td>0</td><td>0</td><td></td><td></td></tr><tr><td>Negative</td><td>0</td><td>50</td><td>50</td><td>100.0% (50/50)</td><td>94.2% - 100.0%</td></tr></table>

HSV 1 & 2 Performance in a Low Prevalence Population   

<table><tr><td rowspan=1 colspan=1>Invalid</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Site Total</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>HSV 2</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>PositiveEquivocalNegatlveInvalid</td><td rowspan=1 colspan=1>48000</td><td rowspan=1 colspan=1>10510</td><td rowspan=1 colspan=1>490510</td><td rowspan=1 colspan=1>100.0% (48/48)98.1% (51/52)</td><td rowspan=1 colspan=1>94.0% - 100.0%94.3% - 100.0%</td></tr><tr><td rowspan=1 colspan=1>Site Total</td><td rowspan=1 colspan=1>48</td><td rowspan=1 colspan=1>52</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr></table>

The relative specificity of HSv 1 & 2 was assessed internally using sera from a low prevalence population. The low prevalence population was comprised of serum samples from 18 and 19 year old subjects previously tested for infections considered non-sexual in nature.

HSV-1 Reactivity: The predicate immunoblot device was positive for 7 samples and negative for 60 samples. The AtheNA Multi-Lyte HSV 1& 2 IgG test system agreed with $8 5 . 7 \%$ (6/7) of immunoblot positives and $9 8 . 3 \%$ (59/60) of immunoblot negatives.

HSV-2 Reactivity: The predicate immunoblot device was positive for 0 samples and negative for 67 samples. The AtheNA Multi-Lyte HSV 1& 2 IgG test system agreed with $100 \%$ (0/0) of immunoblot positives and $100 \%$ (67/67) of immunoblot negatives.

Performance in Low Prevalence Population   

<table><tr><td colspan="2" rowspan="2"></td><td colspan="6">Predicate</td></tr><tr><td>Positlve</td><td>Equivocal</td><td>Negative</td><td>Site Total</td><td>PPA NPA</td><td>95% CI</td></tr><tr><td rowspan="7">Aid T t Vau</td><td>HSV1 Positive</td><td>8</td><td></td><td>2</td><td>10</td><td>100.0% (8/8)</td><td>68.8% - 100%</td></tr><tr><td>Equlvocal Negatlve</td><td>0 0</td><td>0 0 0</td><td>0 56</td><td>0 56</td><td>96.6% (56/58)</td><td>88.1% - 99.6%</td></tr><tr><td>Invalid</td><td>0</td><td>0</td><td>0</td><td>0</td><td></td><td></td></tr><tr><td>Site Total</td><td>8</td><td>0</td><td>58</td><td>66</td><td></td><td></td></tr><tr><td colspan="7"></td></tr><tr><td>HSV 2 Positive</td><td>3</td><td>0</td><td>1</td><td>4</td><td>100.0% (3/3)</td><td>36.8% - 100%</td></tr><tr><td>Equivocal Negative invalid</td><td>0 0</td><td>0 0 0</td><td>0 62</td><td>0 62</td><td>98.4% (62/63)</td><td>91.5% · 100%</td></tr><tr><td></td><td>Site Total</td><td>3</td><td>0</td><td>63</td><td>66</td><td></td><td></td></tr></table>

# Rubella Retrospective Negative Sample Study

The relative specificity of Rubella was assessd internally at Zeus using pre-selected banked sampleso sera which previously tested negative for Rubella antibody by the predicate device.

Rubella Reactivity: The predicate ELISA device was positive for 0 samples and negative for 100 samples. The Rubella analyte in the AtheNA Multi-Lyte ToRCH IgG Plus test system agreed with $100 \%$ (0/0) of ELISA positives and $100 \%$ (100/100) of ELISA negatives.

Rubella Retrospective Negative Sample Study   

<table><tr><td colspan="2"></td><td colspan="6">Predicate</td></tr><tr><td colspan="2"></td><td>Positlve</td><td>Equivocal</td><td>Negative</td><td>Site Total</td><td>PPA NPA</td><td>95% CI</td></tr><tr><td rowspan="5">Aau M - VNl</td><td>Rubella</td><td></td><td></td><td></td><td></td><td></td><td>NVA</td></tr><tr><td>Positive Indeterminate</td><td>0</td><td>0</td><td>0</td><td>0</td><td>N/A</td><td></td></tr><tr><td>Negative</td><td>0 0</td><td>0</td><td>0 100</td><td>0 100</td><td>100.0% 100/100)</td><td>97.1% - 100%</td></tr><tr><td>Invalld</td><td>0</td><td>0 0</td><td>0</td><td>0</td><td></td><td></td></tr><tr><td>Site Total</td><td>0</td><td>0</td><td>100</td><td>100</td><td></td><td></td></tr></table>

# Clinical performance with International Standards

Performance of the AtheNA Multi-Lyte ToRCH IgG Plus was assessed using the CDC Reference Panels. Traceability and linearity was demonstrated for Rubella using the WHO standard. The performance of Rubella IgG was demonstrated using the CDC low titer standard.

# Rubella Traceability to WHO Standard

Traceability was investigated internally to assess the device's correlation to the WHO Standard at the cut- The Standard was diluted and tested in duplicate with the device on two lot numbers and the Percent Recovery calculated. At the WHO Standard dilution of 10.63, the mean of the results on Lot 1 was 9.1 with a recovery of $9 6 \%$ . The mean of results for Lot 2 was 10 with a recovery of $102 \%$ .

Rubella Traceability Study   

<table><tr><td>Expected</td><td colspan="4">AtheNA Multi-Lyte lot 1</td><td colspan="4">AtheNA Multi-Lyte lot 2</td></tr><tr><td>Result</td><td colspan="2">Measured Mean</td><td colspan="2">Mean % Recovery</td><td colspan="2">Measured Mean</td><td colspan="2">Mean % Recovery</td></tr><tr><td>IU/mL</td><td>Result</td><td>1U/mL</td><td>Result</td><td>IU/mL</td><td>Result</td><td>IU/mL.</td><td>Result</td><td>1U/mL</td></tr><tr><td>1.33</td><td>3</td><td>2.7</td><td>210</td><td>205</td><td>3</td><td>2.7</td><td>231</td><td>205</td></tr><tr><td>2.66</td><td>4</td><td>3.6</td><td>148</td><td>137</td><td>4</td><td>3.6</td><td>146</td><td>137</td></tr><tr><td>5.31</td><td>6</td><td>5.5</td><td>110</td><td>103</td><td>6</td><td>5.5</td><td>105</td><td>103</td></tr></table>

<table><tr><td>10.63</td><td>10</td><td>9.1</td><td></td><td>96</td><td>86</td><td>11</td><td>10</td><td>102</td><td>94</td></tr><tr><td>21.25</td><td>20</td><td>18.2</td><td></td><td>96</td><td>86</td><td>20</td><td>18.2</td><td></td><td>86</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>92</td><td></td></tr></table>

# Rubella Low Range Study

ARubella IgG low range linearity study was performed to demonstrate linearity across the lower range o the assay using the WHO Standard The Standard was diluted in duplicate, the means established and the percent recovery of the expected results calculated.

![](images/c96026026bec50c25d6620fedba1f6662e8e2af0e3e5bb5ec7fd727a66f704cc.jpg)

Rubella Performance with CDC Low Titer Standard   
Rubella performance was assessed with the CDC low titer sample $( 2 1 1 \mathsf { U } / \mathsf { m } \mathsf { L } )$ The sample was aliquoted, diluted in duplicate and tested by three technicians. Percent recovery was calculated for both neat and diluted samples

Rubella Performance With CDC Low Titer Sample   

<table><tr><td></td><td colspan="5">CDC Low Titer Rubella Standard: 21 |U/mL</td></tr><tr><td>Tech</td><td>Neat Interpretation</td><td></td><td>% Recovery</td><td>1:2 Dilution</td><td>Interpretation</td><td>% Recovery</td></tr><tr><td>1</td><td>22</td><td>Positive</td><td>102%</td><td>11</td><td>Positive</td><td>102%</td></tr><tr><td>1</td><td>20</td><td>Positive</td><td>93%</td><td>10</td><td>Positive</td><td>99%</td></tr><tr><td>2</td><td>22</td><td>Positive</td><td>103%</td><td>11</td><td>Positive</td><td>109%</td></tr><tr><td>2</td><td>22</td><td>Positive</td><td>105%</td><td>11</td><td>Positive</td><td>104%</td></tr><tr><td>3</td><td>20</td><td>Positive</td><td>95%</td><td>11</td><td>Positive</td><td>101%</td></tr><tr><td>3</td><td>21</td><td>Positive</td><td>100%</td><td>12</td><td>Positive</td><td>111%</td></tr></table>

# Precision and Reproducibility

As precision an erucbilty was evaluatntenally nd at wo extenal ciicl seThe udy was conducted as follows:A panel  i samples was ientid and/or prepared by Zeus Scientc, foru n the study base upon the activity n heAtheNA Multi-yte assay. Two sample  the panel were negative, two were high positives and the other two samples were near the assay cut off for each spec arget. To ssess reproducibility, each sample was aliquoted twice and each aliquot wasnn tplh y.This u  ult per y.Ti was  re ys  c the resulting data used to assess precision at each facility

<table><tr><td rowspan="2">I Member</td><td rowspan="2">Sample N</td><td>Mean</td><td colspan="2">Within-Run</td><td colspan="3">Between-Day</td><td colspan="3">Between-Run</td><td colspan="3">Between-Site Total</td></tr><tr><td>AU/mL</td><td>SD</td><td>%CV</td><td>SD</td><td>%CV</td><td>SD</td><td>%CV</td><td>SD</td><td>%CV</td><td>SD</td><td>%CV</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Toxo IgG Positive 1</td><td>54</td><td>747.2</td><td>52.1</td><td>7.3</td><td>61.6</td><td>8.5</td><td>34.5</td><td>4.7</td><td>71.5</td><td>8.7</td><td>157.2</td><td>8.0</td></tr><tr><td>Toxo IgG Positive 2</td><td>54</td><td>770.3</td><td>50.8</td><td>6.8</td><td>63.1</td><td>8.3</td><td>39.2</td><td>4.9</td><td>78.7</td><td>8.5</td><td>170.3</td><td>8.6</td></tr><tr><td>Toxo IgG Positive 1 (near Cut- off)</td><td>54</td><td>158.8</td><td>158.8</td><td>9.3</td><td>18.2</td><td>11.3</td><td>12.6</td><td>8.0</td><td>18.8</td><td>12.1</td><td>29.5</td><td>11.9</td></tr><tr><td>Toxo IgG Positive 2 (near Cut- off)</td><td>54</td><td>140.2</td><td>140.2</td><td>8.4</td><td>16.8</td><td>11.3</td><td>13.0</td><td>8.3</td><td>20.2</td><td>12.1</td><td>33.2</td><td>12.9</td></tr><tr><td>Toxo IgG Negative 1</td><td>54</td><td>10.5</td><td>10.5</td><td>40.9</td><td>3.8</td><td>39.7</td><td>1.3</td><td>15.0</td><td>4.3</td><td>38.4</td><td>5.0</td><td>40.7</td></tr><tr><td>Toxo IgG Negative 2</td><td>54</td><td>9.1</td><td>9.1</td><td>45.4</td><td>4.1</td><td>47.4</td><td>2.4</td><td>22.6</td><td>4.7</td><td>48.0</td><td>5.6</td><td>49.8</td></tr><tr><td>Rubella IgG Positive 1</td><td>54</td><td>1296.9</td><td>50.1</td><td>3.9</td><td>68.4</td><td>5.0</td><td>54.5</td><td>3.7</td><td>95.4</td><td>5.3</td><td>301.3</td><td>5.7</td></tr><tr><td>Rubella IgG Positivetive 2</td><td>54</td><td>1102.6</td><td>58.2</td><td>5.4</td><td>63.6</td><td>5.8</td><td>37.3</td><td>3.4</td><td>99.5</td><td>6.5</td><td>173.1</td><td>7.0</td></tr><tr><td>RubellaIgG Positive 1 (near Cut-off)</td><td>54</td><td>242.8</td><td>13.3</td><td>5.4</td><td>15.6</td><td>6.5</td><td>10.2</td><td>4.4</td><td>25.6</td><td>6.2</td><td>51.9</td><td>6.4</td></tr><tr><td>Rubella IgG Positive  ne Cut-off)</td><td>54</td><td>189.9</td><td>10.1</td><td>5.2</td><td>15.5</td><td>9.5</td><td>11.5</td><td>5.7</td><td>28.3</td><td>10.1</td><td>37.9</td><td>10.4</td></tr><tr><td>Rubella IgG Negative 1</td><td>54</td><td>27.9</td><td>4.8</td><td>20.5</td><td>16.1</td><td>21.9</td><td>1.8</td><td>8.3</td><td>4.2</td><td>21.3</td><td>19.4</td><td>19.3</td></tr><tr><td>Rubella IgG Negative 2</td><td>54</td><td>47.4</td><td>4.0</td><td>10.3</td><td>6.5</td><td>9.8</td><td>3.7</td><td>9.4</td><td>8.8</td><td>10.9</td><td>23.8</td><td>11.0</td></tr><tr><td>CMV IgG Positive 1</td><td>54</td><td>996.5</td><td>88.2</td><td>8.5</td><td>99.2</td><td>9.7</td><td>58.5</td><td>5.9</td><td>108.2</td><td>10.1</td><td>167.2</td><td>10.0</td></tr><tr><td>CMV IgG Positive 2</td><td>54</td><td>756.9</td><td>54.5</td><td>7.0</td><td>66.7</td><td>8.7</td><td>46.8</td><td>6.3</td><td>73.3</td><td>8.8</td><td>1.6.3</td><td>8.7</td></tr><tr><td>CMV IgG Positive 1 (near Cut- off)</td><td>54</td><td>119.2</td><td>10.1</td><td>8.2</td><td>13.2</td><td>11.1</td><td>9.6</td><td>8.3</td><td>14.9</td><td>10.9</td><td>18.3</td><td>10.1</td></tr><tr><td>CMV IgG Positive 2 (near Cut- off)</td><td>54</td><td>135.3</td><td>13.6</td><td>9.9</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>CMV IgG Negative 1</td><td>54</td><td>17.9</td><td>5.6</td><td>29.8</td><td>16.4 6.1</td><td>12.1 32.7</td><td>12.6 3.4</td><td>9.4 19.5</td><td>19.5 6.3</td><td>10.7 28.2</td><td>21.2 7.4</td><td>10.8 27.1</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>CMV IgG Negative 2</td><td>54</td><td>16.4</td><td>5.5</td><td>35.5</td><td>5.9</td><td>37.1</td><td>3.6</td><td>23.4</td><td>6.3</td><td>35.4</td><td>7.3</td><td>35.4</td></tr><tr><td></td><td>54</td><td>310.1</td><td>24.2</td><td>7.9</td><td>24.8</td><td>8.1</td><td>10</td><td>3.3</td><td></td><td></td><td></td><td></td></tr><tr><td>HSV 1 IgG Positive 1 HSV 1 IgG Positive 2</td><td>54</td><td>392.7</td><td>31.5</td><td>8.0</td><td>32.3</td><td>8.2</td><td>15.6</td><td>3.8</td><td>31 48.1</td><td>8.9 8.7</td><td>32.3 50.8</td><td>10.1 8.4</td></tr><tr><td>HSV 1 IgG Positive 1 (near Cut-</td><td></td><td></td><td></td><td></td><td></td><td>:</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>off) HSV 1 IgG Positive 2 (near Cut-</td><td>54</td><td>144.6</td><td>15.4</td><td>10.7</td><td>17.2</td><td>12.0</td><td>8.9</td><td>6.0</td><td>22.3</td><td>12.4</td><td>23.0</td><td>12.4</td></tr><tr><td>off) HSV 1 IgG Negative 1</td><td>54</td><td>191.7</td><td>17.6</td><td>9.1</td><td>19.7</td><td>10.2</td><td>9.6</td><td>5.1</td><td>24.5</td><td>9.9</td><td>27.4</td><td>10.6</td></tr><tr><td>HSV 1 IgG Negative 2</td><td>54 54</td><td>26.4 8.2</td><td>3.9 2.3</td><td>15.5 30.7</td><td>3.9 2.5</td><td>15.5 34.1</td><td>1.4 1.3</td><td>5.2 17.0</td><td>4.8 2.7</td><td>16.2 36.9</td><td>6.1 3.5</td><td>16.8 39.4</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>HSV 2 IgG Positive 1</td><td>54</td><td>445.7</td><td>26.9</td><td>6.1</td><td>40.1</td><td>8.9</td><td>33.8</td><td>7.4</td><td>53.4</td><td>9.2</td><td>58.1</td><td>9.1</td></tr><tr><td>HSV 2 IgG Positive 2 HSV 2 IgG Positive 1 (near Cut-</td><td>54</td><td>355.6</td><td>27.0</td><td>7.4</td><td>30.5</td><td>8.4</td><td>18.8</td><td>5.2</td><td>51.5</td><td>8</td><td>57.2</td><td>8.6</td></tr><tr><td>off) HSV 2 IgG Positive 2 (near Cut-</td><td>54</td><td>152.2</td><td>14.9</td><td>9.9</td><td>16.0</td><td>10.6</td><td>7.6</td><td>5.2</td><td>25.3</td><td>10.0</td><td>31.6</td><td>11.2</td></tr><tr><td>off)</td><td>54</td><td>114.1</td><td>11.4</td><td>9.8</td><td>12.5</td><td>10.9</td><td>6.3</td><td>5.7</td><td>15.4</td><td>10.8</td><td>20.4</td><td>10.8</td></tr><tr><td>HSV 2 IgG Negative 1</td><td>54</td><td>16.9</td><td>4.0</td><td>29.7</td><td>4.3</td><td>31.3</td><td>2.0</td><td>12.1</td><td>4.3</td><td>35.8</td><td>7.0</td><td>41.0</td></tr><tr><td>HSV 1 IgG Negative 2</td><td>54</td><td>21.2</td><td>5.9</td><td>27.5</td><td>6.5</td><td>30.6</td><td>3.1</td><td>15.2</td><td>6.8</td><td>26.6</td><td>8.9</td><td>27.6</td></tr></table>

<table><tr><td colspan="10">AtheNA Multi-Lyte Torch IgG Plus lot#09046891</td></tr><tr><td>WHO Value</td><td colspan="7">Rubella IgG</td><td colspan="2"></td></tr><tr><td></td><td>AU</td><td>U/ml</td><td>converted IU/mL</td><td>AU</td><td>U/ml</td><td>converted IU/mL</td><td>Mean(U/mL)</td><td></td><td>converted IU/mL</td></tr><tr><td>21.25</td><td>198</td><td>18</td><td>17</td><td>245</td><td></td><td>22</td><td>20</td><td>20</td><td>18</td></tr><tr><td>10.63</td><td>122</td><td>11</td><td>10 &#x27;:</td><td>101</td><td>9</td><td>8</td><td></td><td>10</td><td>9</td></tr><tr><td>5.31</td><td>57</td><td>5</td><td>5</td><td>71</td><td>7</td><td></td><td>6</td><td>6</td><td>5</td></tr><tr><td>2.66</td><td>45</td><td>4</td><td>4</td><td>41</td><td>4</td><td>3</td><td></td><td>4</td><td>4</td></tr><tr><td>1.33</td><td>25</td><td>2</td><td>2</td><td>36</td><td>3</td><td>3</td><td></td><td>3</td><td>3</td></tr></table>

<table><tr><td></td><td>Means</td></tr><tr><td>WHO Value IU</td><td>U/mL</td></tr><tr><td>21.25 10.63</td><td>20</td></tr><tr><td>5.31</td><td>10 6</td></tr><tr><td>2.66</td><td>4</td></tr><tr><td>1.33</td><td>3</td></tr></table>

![](images/bb9bdf80abae85796d76b88e12856df8d455dca0d480c7062b6aff5640ba5fb8.jpg)

<table><tr><td>WHO Value IU</td><td>Converted Means IU/mL</td></tr><tr><td>21.25</td><td>18.</td></tr><tr><td>10.63</td><td>9</td></tr><tr><td>5.31</td><td>5</td></tr><tr><td>2.66</td><td>4</td></tr><tr><td>1.33</td><td>3</td></tr></table>

Zeus Scientific Inc. c/o Ms. Ewa Nadolczak Manager Clinical Affairs 200 Evans Way Branchburg, NJ 08876

Re: K093784 Trade/Device Name: AtheNA Multi-Lyte $\textcircled{8}$ ToRCH IgG Plus Test System Regulation Number: 21 CFR 866.3510 Regulation Name: Rubella Virus Serological Reagents. Regulatory Class: Class II Product Code: OPM, LGD, LFZ, MXJ, MYF Dated: July 12, 2010 Received: July 13, 2010

Dear Ms. Nadolczak:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially.equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (seeabove) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your devicé complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with al the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of

medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796- 5450.Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its-Internet address   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours, Jaattor

Sally A. Hojvat, M.S., Ph.D.   
Director   
Division of Microbiology Devices   
Office of In Vitro Device Evaluation and Safety Center for Devices and Radiological Health

Enclosure

# Indications for Use

510(k) Number: k093784

Device Name: AtheNA Multi-Lyte® ToRCH IgG Plus Test System.

Indications for Use:

The Zeus Scientific, Inc. AtheNA Multi-Lyte® ToRCH IgG Plus Test System is intended for the qualitative detection of specific human IgG class antibodies to Toxoplasma gondii (T.gondii), Rubella, Cytomegalovirus (CMV) and HSV 1 & 2 in human serum. The results of this assay are intended to be used as an aid in the assessment of serological status to Toxoplasma gondii, Rubella and CMV. For HSV 1 and HSV 2, the test is indicated for sexually active adults and expectant mothers, as an aid for presumptively diagnosing Herpes Simplex 1 and Herpes Simplex 2.

The test is not intended for use in screening blood or plasma donors.

The performance of this assay has not been established for use in a pediatric population, neonatal screening, immunocompromised or immunosuppressed patients or for use at point of care facilities.

Prescription Use X AND/OR Over-The-Counter Use (Part 21 CFR 801 Subpart D) (21 CFR 807 Subpart C)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

![](images/ac38a7014e78e9ebabe077f71bda3c6dc1bbc5e477dc7884b12661f253a5861b.jpg)

Division Sign-Off

Office of In Vitro Diagnostic Device Evaluation and Safety

Page 1 of _1

510(k) k 093784